Latest News

Montu, a provider of telehealth services, has been invited to contribute to the Productivity Commission’s national inquiry into data, digital technology, and delivering quality care more efficiently.

Pharmac’s board has appointed Canadian Natalie McMurtry to succeed Sarah Fitt as the organisation's new chief executive.

The US FDA has approved CSL's ANDEMBRY for hereditary angioedema, enabling its launch in the country.

Many people have formed a view of the US health system based on public critiques, which appear to be influenced by television dramas rather than direct experience of the system.

The US FDA has approved an Investigational New Drug, enabling the Melbourne-based company Myrio to progress its lead product into human clinical trials.

The oft-repeated claim that, unlike in Australia, Americans are forced to present their credit cards to access healthcare belies the complex reality and the fact that they have been a long-standing, ubiquitous feature of accessing healthcare in this country.

A UK report has confirmed the country's decision to review medicine prices to take into account the “concerns of the president”.

Amplia Therapeutics (ASX:ATX) has announced important new data from its ongoing ACCENT clinical trial in pancreatic cancer.

How bad was that original risk-share? Sanofi had to threaten to remove their therapy from the PBS for atopic dermatitis to secure any changes, and it remains so bad that Lilly is not going to list EBGLYSS.

Lilly General Manager Tori Brown said, “The Government has acknowledged patients face delays in accessing PBS-reimbursed treatments. Now, more than ever, HTA reform must be a key priority – without it, Australians will continue to miss out on the world’s latest medicines.”

The industry is in a difficult position. It is caught between wanting to satisfy the demands of the Trump administration while protecting its most important market and having minimal control over its negotiations with other countries. In other words, it is part stakeholder, participant and spectator.

The global initiative aims to engage governments, institutions, enterprises, and organisations in submitting innovative proposals that integrate Taiwan’s home-grown health innovations.